Share Twitter LinkedIn Facebook Email Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: how this affects clinicians, patients and treatment today.
Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD Prostate 2 Mins Read
Pioneering Advances in Non-Metastatic Prostate Cancer: Navigating ARPIs and Precision Diagnostics for Tailored Treatment [39 SLIDES] Prostate 5 Mins Read
Promontory Therapeutics: PT-112 triggers organelle stress and ribosomal inhibition Prostate 2 Mins Read
